25 XP   0   0   10

Hebei Changshan Biochem Pharma
Buy, Hold or Sell?

Let's analyse Hebei Changshan Biochem Pharma together

PenkeI guess you are interested in Hebei Changshan Biochem Pharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hebei Changshan Biochem Pharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hebei Changshan Biochem Pharma

I send you an email if I find something interesting about Hebei Changshan Biochem Pharma.

Quick analysis of Hebei Changshan Biochem Pharma (30 sec.)










What can you expect buying and holding a share of Hebei Changshan Biochem Pharma? (30 sec.)

How much money do you get?

How much money do you get?
¥0.07
When do you have the money?
1 year
How often do you get paid?
90.0%

What is your share worth?

Current worth
¥3.27
Expected worth in 1 year
¥3.19
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
¥0.45
Return On Investment
3.8%

For what price can you sell your share?

Current Price per Share
¥11.97
Expected price per share
¥6.6649 - ¥14.34
How sure are you?
50%

1. Valuation of Hebei Changshan Biochem Pharma (5 min.)




Live pricePrice per Share (EOD)

¥11.97

Intrinsic Value Per Share

¥-6.35 - ¥-4.04

Total Value Per Share

¥-3.08 - ¥-0.77

2. Growth of Hebei Changshan Biochem Pharma (5 min.)




Is Hebei Changshan Biochem Pharma growing?

Current yearPrevious yearGrowGrow %
How rich?$421.4m$423.9m-$2.4m-0.6%

How much money is Hebei Changshan Biochem Pharma making?

Current yearPrevious yearGrowGrow %
Making money$2.4m$32.2m-$29.8m-1,233.7%
Net Profit Margin0.7%7.9%--

How much money comes from the company's main activities?

3. Financial Health of Hebei Changshan Biochem Pharma (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#137 / 1010

Most Revenue
#44 / 1010

Most Profit
#129 / 1010

Most Efficient
#157 / 1010

What can you expect buying and holding a share of Hebei Changshan Biochem Pharma? (5 min.)

Welcome investor! Hebei Changshan Biochem Pharma's management wants to use your money to grow the business. In return you get a share of Hebei Changshan Biochem Pharma.

What can you expect buying and holding a share of Hebei Changshan Biochem Pharma?

First you should know what it really means to hold a share of Hebei Changshan Biochem Pharma. And how you can make/lose money.

Speculation

The Price per Share of Hebei Changshan Biochem Pharma is ¥11.97. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hebei Changshan Biochem Pharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hebei Changshan Biochem Pharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥3.27. Based on the TTM, the Book Value Change Per Share is ¥-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.13 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hebei Changshan Biochem Pharma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.000.0%0.000.0%0.030.3%0.030.2%0.020.2%
Usd Book Value Change Per Share0.000.0%0.000.0%0.030.3%0.020.2%0.030.2%
Usd Dividend Per Share0.020.2%0.020.2%0.010.1%0.010.1%0.010.1%
Usd Total Gains Per Share0.020.1%0.020.1%0.040.3%0.030.2%0.040.3%
Usd Price Per Share0.76-0.76-1.12-0.81-1.70-
Price to Earnings Ratio292.55-292.55-32.54-79.57-102.67-
Price-to-Total Gains Ratio48.38-48.38-27.07-29.77-63.54-
Price to Book Ratio1.68-1.68-2.47-1.91-6.71-
Price-to-Total Gains Ratio48.38-48.38-27.07-29.77-63.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.65186
Number of shares605
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.01
Usd Book Value Change Per Share0.000.02
Usd Total Gains Per Share0.020.03
Gains per Quarter (605 shares)9.4617.97
Gains per Year (605 shares)37.8371.87
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
144-628284462
289-13665588134
3133-1910483133206
4177-26142111177278
5221-32180138221350
6266-39218166265422
7310-45256194309494
8354-52294221354566
9399-58332249398638
10443-65370277442710

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%15.00.00.0100.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%9.01.00.090.0%14.01.00.093.3%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.00.01.090.0%14.00.01.093.3%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%15.00.00.0100.0%

Fundamentals of Hebei Changshan Biochem Pharma

About Hebei Changshan Biochem Pharma

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. It offers crude heparin sodium, heparin sodium raw materials, heparin sodium injections, low molecular weight heparin calcium raw materials and injections, enoxaparin sodium raw materials and injections, nadri heparin calcium API, nandroparin calcium injection, and dalteparin sodium API and injection. The company was founded in 2000 and is based in Shijiazhuang, China.

Fundamental data was last updated by Penke on 2024-04-16 13:35:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Hebei Changshan Biochem Pharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hebei Changshan Biochem Pharma earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • A Net Profit Margin of 0.7% means that ¥0.01 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 0.7%. The company is not making a profit/loss.
  • The TTM is 0.7%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ0.7%TTM0.7%0.0%
TTM0.7%YOY7.9%-7.1%
TTM0.7%5Y7.7%-7.0%
5Y7.7%10Y11.8%-4.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7%-207.2%+207.9%
TTM0.7%-216.8%+217.5%
YOY7.9%-282.3%+290.2%
5Y7.7%-436.8%+444.5%
10Y11.8%-597.3%+609.1%
1.1.2. Return on Assets

Shows how efficient Hebei Changshan Biochem Pharma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • 0.3% Return on Assets means that Hebei Changshan Biochem Pharma generated ¥0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 0.3%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.3%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.3%TTM0.3%0.0%
TTM0.3%YOY4.5%-4.2%
TTM0.3%5Y3.9%-3.6%
5Y3.9%10Y5.1%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3%-13.3%+13.6%
TTM0.3%-12.8%+13.1%
YOY4.5%-11.6%+16.1%
5Y3.9%-13.8%+17.7%
10Y5.1%-15.6%+20.7%
1.1.3. Return on Equity

Shows how efficient Hebei Changshan Biochem Pharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • 0.6% Return on Equity means Hebei Changshan Biochem Pharma generated ¥0.01 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 0.6%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.6%TTM0.6%0.0%
TTM0.6%YOY7.6%-7.0%
TTM0.6%5Y6.2%-5.6%
5Y6.2%10Y7.7%-1.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6%-16.9%+17.5%
TTM0.6%-16.1%+16.7%
YOY7.6%-14.9%+22.5%
5Y6.2%-19.3%+25.5%
10Y7.7%-20.1%+27.8%

1.2. Operating Efficiency of Hebei Changshan Biochem Pharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hebei Changshan Biochem Pharma is operating .

  • Measures how much profit Hebei Changshan Biochem Pharma makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • An Operating Margin of 4.6% means the company generated ¥0.05  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 4.6%. The company is operating less efficient.
  • The TTM is 4.6%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ4.6%TTM4.6%0.0%
TTM4.6%YOY10.9%-6.3%
TTM4.6%5Y12.6%-7.9%
5Y12.6%10Y12.8%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6%-298.0%+302.6%
TTM4.6%-238.5%+243.1%
YOY10.9%-288.4%+299.3%
5Y12.6%-486.2%+498.8%
10Y12.8%-628.4%+641.2%
1.2.2. Operating Ratio

Measures how efficient Hebei Changshan Biochem Pharma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.50 means that the operating costs are ¥1.50 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 1.498. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.498. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.498TTM1.4980.000
TTM1.498YOY1.305+0.193
TTM1.4985Y1.236+0.261
5Y1.23610Y1.040+0.197
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4983.235-1.737
TTM1.4983.310-1.812
YOY1.3053.838-2.533
5Y1.2365.679-4.443
10Y1.0407.823-6.783

1.3. Liquidity of Hebei Changshan Biochem Pharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hebei Changshan Biochem Pharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.18 means the company has ¥2.18 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 2.180. The company is able to pay all its short-term debts. +1
  • The TTM is 2.180. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.180TTM2.1800.000
TTM2.180YOY1.966+0.214
TTM2.1805Y2.159+0.020
5Y2.15910Y1.861+0.298
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1803.863-1.683
TTM2.1804.169-1.989
YOY1.9665.337-3.371
5Y2.1596.122-3.963
10Y1.8616.434-4.573
1.3.2. Quick Ratio

Measures if Hebei Changshan Biochem Pharma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • A Quick Ratio of 0.22 means the company can pay off ¥0.22 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 0.224. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.224. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.224TTM0.2240.000
TTM0.224YOY0.205+0.018
TTM0.2245Y0.272-0.048
5Y0.27210Y0.306-0.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2243.504-3.280
TTM0.2243.991-3.767
YOY0.2055.371-5.166
5Y0.2726.088-5.816
10Y0.3066.395-6.089

1.4. Solvency of Hebei Changshan Biochem Pharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hebei Changshan Biochem Pharma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hebei Changshan Biochem Pharma to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.49 means that Hebei Changshan Biochem Pharma assets are financed with 49.4% credit (debt) and the remaining percentage (100% - 49.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 0.494. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.494. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.494TTM0.4940.000
TTM0.494YOY0.408+0.086
TTM0.4945Y0.386+0.108
5Y0.38610Y0.336+0.051
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4940.339+0.155
TTM0.4940.337+0.157
YOY0.4080.271+0.137
5Y0.3860.368+0.018
10Y0.3360.388-0.052
1.4.2. Debt to Equity Ratio

Measures if Hebei Changshan Biochem Pharma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • A Debt to Equity ratio of 97.5% means that company has ¥0.98 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 0.975. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.975. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.975TTM0.9750.000
TTM0.975YOY0.690+0.285
TTM0.9755Y0.649+0.326
5Y0.64910Y0.533+0.116
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9750.392+0.583
TTM0.9750.403+0.572
YOY0.6900.335+0.355
5Y0.6490.427+0.222
10Y0.5330.461+0.072

2. Market Valuation of Hebei Changshan Biochem Pharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Hebei Changshan Biochem Pharma generates.

  • Above 15 is considered overpriced but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • A PE ratio of 292.55 means the investor is paying ¥292.55 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hebei Changshan Biochem Pharma:

  • The EOD is 639.026. Based on the earnings, the company is expensive. -2
  • The MRQ is 292.553. Based on the earnings, the company is expensive. -2
  • The TTM is 292.553. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD639.026MRQ292.553+346.472
MRQ292.553TTM292.5530.000
TTM292.553YOY32.543+260.010
TTM292.5535Y79.569+212.985
5Y79.56910Y102.670-23.101
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD639.026-2.300+641.326
MRQ292.553-2.656+295.209
TTM292.553-2.718+295.271
YOY32.543-4.145+36.688
5Y79.569-6.258+85.827
10Y102.670-6.315+108.985
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hebei Changshan Biochem Pharma:

  • The EOD is -26.143. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.968. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -11.968. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-26.143MRQ-11.968-14.174
MRQ-11.968TTM-11.9680.000
TTM-11.968YOY-24.905+12.937
TTM-11.9685Y-1.786-10.182
5Y-1.78610Y144.540-146.326
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-26.143-2.974-23.169
MRQ-11.968-3.306-8.662
TTM-11.968-3.508-8.460
YOY-24.905-5.613-19.292
5Y-1.786-8.378+6.592
10Y144.540-8.873+153.413
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hebei Changshan Biochem Pharma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.68 means the investor is paying ¥1.68 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Hebei Changshan Biochem Pharma:

  • The EOD is 3.665. Based on the equity, the company is fair priced.
  • The MRQ is 1.678. Based on the equity, the company is underpriced. +1
  • The TTM is 1.678. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.665MRQ1.678+1.987
MRQ1.678TTM1.6780.000
TTM1.678YOY2.474-0.797
TTM1.6785Y1.912-0.235
5Y1.91210Y6.713-4.800
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.6651.914+1.751
MRQ1.6782.116-0.438
TTM1.6782.097-0.419
YOY2.4742.881-0.407
5Y1.9123.550-1.638
10Y6.7133.936+2.777
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hebei Changshan Biochem Pharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.019-0.0190%0.234-108%0.132-115%0.204-109%
Book Value Per Share--3.2663.2660%3.286-1%3.043+7%2.497+31%
Current Ratio--2.1802.1800%1.966+11%2.159+1%1.861+17%
Debt To Asset Ratio--0.4940.4940%0.408+21%0.386+28%0.336+47%
Debt To Equity Ratio--0.9750.9750%0.690+41%0.649+50%0.533+83%
Dividend Per Share--0.1330.1330%0.066+100%0.083+60%0.061+117%
Eps--0.0190.0190%0.250-93%0.186-90%0.177-89%
Free Cash Flow Per Share---0.458-0.4580%-0.326-29%-0.274-40%-0.177-61%
Free Cash Flow To Equity Per Share---0.458-0.4580%0.040-1234%-0.155-66%0.002-20318%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---4.036--------
Intrinsic Value_10Y_min---6.346--------
Intrinsic Value_1Y_max---0.227--------
Intrinsic Value_1Y_min---0.463--------
Intrinsic Value_3Y_max---0.817--------
Intrinsic Value_3Y_min---1.549--------
Intrinsic Value_5Y_max---1.570--------
Intrinsic Value_5Y_min---2.800--------
Market Cap11001160074.240+53%5123618491.4405123618491.4400%7601280718.140-33%5482645772.592-7%11353820578.474-55%
Net Profit Margin--0.0070.0070%0.079-90%0.077-90%0.118-94%
Operating Margin--0.0460.0460%0.109-58%0.126-63%0.128-64%
Operating Ratio--1.4981.4980%1.305+15%1.236+21%1.040+44%
Pb Ratio3.665+54%1.6781.6780%2.474-32%1.912-12%6.713-75%
Pe Ratio639.026+54%292.553292.5530%32.543+799%79.569+268%102.670+185%
Price Per Share11.970+54%5.4805.4800%8.130-33%5.864-7%12.292-55%
Price To Free Cash Flow Ratio-26.143-118%-11.968-11.9680%-24.905+108%-1.786-85%144.540-108%
Price To Total Gains Ratio105.678+54%48.38048.3800%27.072+79%29.771+63%63.541-24%
Quick Ratio--0.2240.2240%0.205+9%0.272-18%0.306-27%
Return On Assets--0.0030.0030%0.045-94%0.039-93%0.051-94%
Return On Equity--0.0060.0060%0.076-92%0.062-91%0.077-93%
Total Gains Per Share--0.1130.1130%0.300-62%0.215-47%0.265-57%
Usd Book Value--421455285.061421455285.0610%423952503.326-1%392600913.236+7%320616139.578+31%
Usd Book Value Change Per Share---0.003-0.0030%0.032-108%0.018-115%0.028-109%
Usd Book Value Per Share--0.4510.4510%0.453-1%0.420+7%0.345+31%
Usd Dividend Per Share--0.0180.0180%0.009+100%0.011+60%0.008+117%
Usd Eps--0.0030.0030%0.034-93%0.026-90%0.024-89%
Usd Free Cash Flow---59077201.190-59077201.1900%-42119087.295-29%-35334516.683-40%-18275408.248-69%
Usd Free Cash Flow Per Share---0.063-0.0630%-0.045-29%-0.038-40%-0.024-61%
Usd Free Cash Flow To Equity Per Share---0.063-0.0630%0.006-1234%-0.021-66%0.000-20318%
Usd Market Cap1518160090.245+53%707059351.819707059351.8190%1048976739.103-33%756605116.618-7%1566827239.829-55%
Usd Price Per Share1.652+54%0.7560.7560%1.122-33%0.809-7%1.696-55%
Usd Profit--2416858.1002416858.1000%32233190.029-93%23989977.677-90%22726140.876-89%
Usd Revenue--322399717.753322399717.7530%409591016.240-21%314424175.393+3%225794390.793+43%
Usd Total Gains Per Share--0.0160.0160%0.041-62%0.030-47%0.037-57%
 EOD+5 -3MRQTTM+0 -0YOY+7 -285Y+11 -2410Y+10 -25

3.2. Fundamental Score

Let's check the fundamental score of Hebei Changshan Biochem Pharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15639.026
Price to Book Ratio (EOD)Between0-13.665
Net Profit Margin (MRQ)Greater than00.007
Operating Margin (MRQ)Greater than00.046
Quick Ratio (MRQ)Greater than10.224
Current Ratio (MRQ)Greater than12.180
Debt to Asset Ratio (MRQ)Less than10.494
Debt to Equity Ratio (MRQ)Less than10.975
Return on Equity (MRQ)Greater than0.150.006
Return on Assets (MRQ)Greater than0.050.003
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Hebei Changshan Biochem Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.355
Ma 20Greater thanMa 5010.569
Ma 50Greater thanMa 10011.435
Ma 100Greater thanMa 20011.848
OpenGreater thanClose12.690
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets6,035,803
Total Liabilities2,981,780
Total Stockholder Equity3,058,046
 As reported
Total Liabilities 2,981,780
Total Stockholder Equity+ 3,058,046
Total Assets = 6,035,803

Assets

Total Assets6,035,803
Total Current Assets3,897,553
Long-term Assets2,138,250
Total Current Assets
Cash And Cash Equivalents 797,797
Net Receivables 399,763
Inventory 2,431,477
Other Current Assets 172,242
Total Current Assets  (as reported)3,897,553
Total Current Assets  (calculated)3,801,278
+/- 96,275
Long-term Assets
Property Plant Equipment 1,483,330
Goodwill 1,778
Intangible Assets 547,954
Long-term Assets Other 86,469
Long-term Assets  (as reported)2,138,250
Long-term Assets  (calculated)2,119,530
+/- 18,720

Liabilities & Shareholders' Equity

Total Current Liabilities1,787,946
Long-term Liabilities1,193,834
Total Stockholder Equity3,058,046
Total Current Liabilities
Short Long Term Debt 971,316
Accounts payable 249,809
Other Current Liabilities 122,560
Total Current Liabilities  (as reported)1,787,946
Total Current Liabilities  (calculated)1,343,685
+/- 444,260
Long-term Liabilities
Long term Debt 1,128,843
Long-term Liabilities  (as reported)1,193,834
Long-term Liabilities  (calculated)1,128,843
+/- 64,991
Total Stockholder Equity
Common Stock934,967
Retained Earnings 1,794,108
Total Stockholder Equity (as reported)3,058,046
Total Stockholder Equity (calculated)2,729,074
+/- 328,972
Other
Capital Stock934,967
Common Stock Shares Outstanding 934,967
Net Debt 1,302,362
Net Invested Capital 5,158,205
Net Tangible Assets 2,792,444
Net Working Capital 2,109,608
Property Plant and Equipment Gross 1,483,330



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-31
> Total Assets 
196,593
266,349
430,639
1,186,221
1,418,450
1,645,301
2,044,758
2,328,271
3,131,972
3,530,047
3,844,837
3,942,592
4,572,557
5,189,849
6,035,803
6,035,8035,189,8494,572,5573,942,5923,844,8373,530,0473,131,9722,328,2712,044,7581,645,3011,418,4501,186,221430,639266,349196,593
   > Total Current Assets 
0
0
0
0
0
0
0
1,434,899
2,105,288
2,329,801
2,603,558
2,534,218
2,999,366
3,408,485
3,897,553
3,897,5533,408,4852,999,3662,534,2182,603,5582,329,8012,105,2881,434,8990000000
       Cash And Cash Equivalents 
1,279
28,482
92,199
741,900
539,526
261,502
238,842
164,485
786,603
797,654
1,020,673
563,310
481,016
543,214
797,797
797,797543,214481,016563,3101,020,673797,654786,603164,485238,842261,502539,526741,90092,19928,4821,279
       Net Receivables 
33,221
27,177
74,214
78,768
128,119
147,279
159,332
165,519
173,022
412,031
360,726
383,746
387,301
356,332
399,763
399,763356,332387,301383,746360,726412,031173,022165,519159,332147,279128,11978,76874,21427,17733,221
       Other Current Assets 
3,121
29,586
6,622
53,572
143,635
357,376
253,104
219,893
152,458
86,234
139,005
178,095
159,641
223,680
172,242
172,242223,680159,641178,095139,00586,234152,458219,893253,104357,376143,63553,5726,62229,5863,121
   > Long-term Assets 
0
0
0
0
0
0
0
0
1,026,684
1,200,246
1,241,279
1,408,374
1,573,191
1,781,363
2,138,250
2,138,2501,781,3631,573,1911,408,3741,241,2791,200,2461,026,68400000000
       Property Plant Equipment 
46,753
45,669
107,110
138,380
277,627
419,252
499,329
565,724
662,447
769,515
849,476
935,317
1,064,193
1,192,553
1,483,330
1,483,3301,192,5531,064,193935,317849,476769,515662,447565,724499,329419,252277,627138,380107,11045,66946,753
       Goodwill 
0
0
0
0
0
0
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
1,778
1,7783,5563,5563,5563,5563,5563,5563,5563,556000000
       Long Term Investments 
0
0
0
0
0
0
0
0
64,553
22,258
8,196
0
0
0
0
00008,19622,25864,55300000000
       Intangible Assets 
28,269
27,589
57,366
56,063
11,273
56,534
113,175
101,827
199,106
251,759
264,170
281,267
401,776
493,127
547,954
547,954493,127401,776281,267264,170251,759199,106101,827113,17556,53411,27356,06357,36627,58928,269
       Long-term Assets Other 
0
0
0
0
0
0
0
0
86,878
139,716
106,239
167,853
65,611
68,096
86,469
86,46968,09665,611167,853106,239139,71686,87800000000
> Total Liabilities 
103,163
107,154
211,253
198,775
292,773
359,779
617,869
757,072
842,591
1,094,656
1,321,812
1,220,318
1,719,329
2,117,729
2,981,780
2,981,7802,117,7291,719,3291,220,3181,321,8121,094,656842,591757,072617,869359,779292,773198,775211,253107,154103,163
   > Total Current Liabilities 
103,163
106,501
197,173
182,482
273,033
334,135
589,819
717,731
736,373
787,880
1,087,225
1,188,125
1,412,071
1,734,044
1,787,946
1,787,9461,734,0441,412,0711,188,1251,087,225787,880736,373717,731589,819334,135273,033182,482197,173106,501103,163
       Short-term Debt 
0
0
0
0
0
0
0
0
540,619
532,000
753,495
0
0
0
0
0000753,495532,000540,61900000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
540,619
532,000
753,495
617,557
1,011,859
1,231,905
971,316
971,3161,231,9051,011,859617,557753,495532,000540,61900000000
       Accounts payable 
11,017
1,581
11,171
3,887
4,261
17,616
34,899
70,813
60,074
38,913
56,739
80,668
82,354
106,490
249,809
249,809106,49082,35480,66856,73938,91360,07470,81334,89917,6164,2613,88711,1711,58111,017
       Other Current Liabilities 
16,346
20,720
11,721
20,095
44,272
52,719
54,920
61,897
76,598
112,734
147,687
176,043
212,391
184,793
122,560
122,560184,793212,391176,043147,687112,73476,59861,89754,92052,71944,27220,09511,72120,72016,346
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
106,217
306,776
234,587
32,193
307,258
383,685
1,193,834
1,193,834383,685307,25832,193234,587306,776106,21700000000
       Other Liabilities 
0
653
14,080
16,293
16,058
22,426
25,210
39,341
106,217
106,776
34,587
32,193
25,846
51,215
0
051,21525,84632,19334,587106,776106,21739,34125,21022,42616,05816,29314,0806530
       Deferred Long Term Liability 
0
0
0
0
0
0
0
29,758
43,813
60,477
80,657
108,093
150,175
219,837
0
0219,837150,175108,09380,65760,47743,81329,7580000000
> Total Stockholder Equity
93,429
159,195
219,385
987,446
1,099,631
1,229,321
1,369,777
1,513,541
2,228,835
2,369,451
2,512,818
2,714,925
2,847,580
3,068,784
3,058,046
3,058,0463,068,7842,847,5802,714,9252,512,8182,369,4512,228,8351,513,5411,369,7771,229,3211,099,631987,446219,385159,19593,429
   Common Stock
49,292
80,850
80,850
107,850
188,419
188,419
188,419
471,047
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967934,967934,967934,967934,967934,967934,967471,047188,419188,419188,419107,85080,85080,85049,292
   Retained Earnings 
8,044
15,697
69,869
133,589
200,908
285,248
456,023
596,305
746,827
929,722
1,051,009
1,326,228
1,566,916
1,800,490
1,794,108
1,794,1081,800,4901,566,9161,326,2281,051,009929,722746,827596,305456,023285,248200,908133,58969,86915,6978,044
   Capital Surplus 000000000000000
   Treasury Stock000000000000000
   Other Stockholders Equity -77,859-73,503-61,133-73,1120-62,122-19,84300000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,682,066
Cost of Revenue-1,177,123
Gross Profit504,942504,942
 
Operating Income (+$)
Gross Profit504,942
Operating Expense-1,913,978
Operating Income-231,913-1,409,036
 
Operating Expense (+$)
Research Development130,153
Selling General Administrative526,652
Selling And Marketing Expenses-
Operating Expense1,913,978656,805
 
Net Interest Income (+$)
Interest Income1,828
Interest Expense-101,176
Other Finance Cost-6,499
Net Interest Income-105,847
 
Pretax Income (+$)
Operating Income-231,913
Net Interest Income-105,847
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-472,516-231,913
EBIT - interestExpense = -101,176
-438,107
-336,930
Interest Expense101,176
Earnings Before Interest and Taxes (EBIT)--371,340
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-472,516
Tax Provision--26,493
Net Income From Continuing Ops-446,023-446,023
Net Income-438,107
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-105,847
 

Technical Analysis of Hebei Changshan Biochem Pharma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hebei Changshan Biochem Pharma. The general trend of Hebei Changshan Biochem Pharma is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hebei Changshan Biochem Pharma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hebei Changshan Biochem Pharma.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 14.10 < 14.23 < 14.34.

The bearish price targets are: 9.18 > 7.56 > 6.6649.

Tweet this
Hebei Changshan Biochem Pharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hebei Changshan Biochem Pharma. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hebei Changshan Biochem Pharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hebei Changshan Biochem Pharma. The current macd is -0.2300038.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hebei Changshan Biochem Pharma price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Hebei Changshan Biochem Pharma. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Hebei Changshan Biochem Pharma price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Hebei Changshan Biochem Pharma Daily Moving Average Convergence/Divergence (MACD) ChartHebei Changshan Biochem Pharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hebei Changshan Biochem Pharma. The current adx is 28.89.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Hebei Changshan Biochem Pharma shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Hebei Changshan Biochem Pharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hebei Changshan Biochem Pharma. The current sar is 9.34118479.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Hebei Changshan Biochem Pharma Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hebei Changshan Biochem Pharma. The current rsi is 61.36. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Hebei Changshan Biochem Pharma Daily Relative Strength Index (RSI) ChartHebei Changshan Biochem Pharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hebei Changshan Biochem Pharma. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hebei Changshan Biochem Pharma price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Hebei Changshan Biochem Pharma Daily Stochastic Oscillator ChartHebei Changshan Biochem Pharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hebei Changshan Biochem Pharma. The current cci is 147.55.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Hebei Changshan Biochem Pharma Daily Commodity Channel Index (CCI) ChartHebei Changshan Biochem Pharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hebei Changshan Biochem Pharma. The current cmo is 40.22.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Hebei Changshan Biochem Pharma Daily Chande Momentum Oscillator (CMO) ChartHebei Changshan Biochem Pharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hebei Changshan Biochem Pharma. The current willr is -26.96335079.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Hebei Changshan Biochem Pharma is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Hebei Changshan Biochem Pharma Daily Williams %R ChartHebei Changshan Biochem Pharma Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hebei Changshan Biochem Pharma.

Hebei Changshan Biochem Pharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hebei Changshan Biochem Pharma. The current atr is 0.69684251.

Hebei Changshan Biochem Pharma Daily Average True Range (ATR) ChartHebei Changshan Biochem Pharma Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hebei Changshan Biochem Pharma. The current obv is 2,788,629,552.

Hebei Changshan Biochem Pharma Daily On-Balance Volume (OBV) ChartHebei Changshan Biochem Pharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hebei Changshan Biochem Pharma. The current mfi is 60.59.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Hebei Changshan Biochem Pharma Daily Money Flow Index (MFI) ChartHebei Changshan Biochem Pharma Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hebei Changshan Biochem Pharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Hebei Changshan Biochem Pharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hebei Changshan Biochem Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.355
Ma 20Greater thanMa 5010.569
Ma 50Greater thanMa 10011.435
Ma 100Greater thanMa 20011.848
OpenGreater thanClose12.690
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hebei Changshan Biochem Pharma with someone you think should read this too:
  • Are you bullish or bearish on Hebei Changshan Biochem Pharma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hebei Changshan Biochem Pharma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hebei Changshan Biochem Pharma

I send you an email if I find something interesting about Hebei Changshan Biochem Pharma.


Comments

How you think about this?

Leave a comment

Stay informed about Hebei Changshan Biochem Pharma.

Receive notifications about Hebei Changshan Biochem Pharma in your mailbox!